---
title: "SMMT: Ivonescimab advances in Phase III, but funding shortfall raises going concern risk"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293661623.md"
description: "Lead oncology asset ivonescimab showed strong PFS results in Phase III trials, but FDA approval hinges on OS significance. Net loss narrowed year-over-year, but liquidity is insufficient for the next 12 months, raising going concern risk.Original document: Summit Therapeutics Inc. [SMMT] SEC 10-Q Quarterly Report — Jul. 23 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-23T20:13:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293661623.md)
  - [en](https://longbridge.com/en/news/293661623.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293661623.md)
---

# SMMT: Ivonescimab advances in Phase III, but funding shortfall raises going concern risk

Lead oncology asset ivonescimab showed strong PFS results in Phase III trials, but FDA approval hinges on OS significance. Net loss narrowed year-over-year, but liquidity is insufficient for the next 12 months, raising going concern risk.

Original document: Summit Therapeutics Inc. \[SMMT\] SEC 10-Q Quarterly Report — Jul. 23 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [SMMT.US](https://longbridge.com/en/quote/SMMT.US.md)

## Related News & Research

- [SMMT: Ivonescimab achieved landmark Phase III survival results and FDA BLA acceptance, with strong cash reserves](https://longbridge.com/en/news/293661481.md)
- [08:52 ETKuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm](https://longbridge.com/en/news/293935876.md)
- [Sam Altman said AI hasn't led to 4-hour workweeks because people are competitive](https://longbridge.com/en/news/293883472.md)
- [Hyperscalers can't win with investors as they spend big on AI](https://longbridge.com/en/news/293912231.md)
- [Summit Therapeutics Flags Going Concern Risk Over Cash Needs](https://longbridge.com/en/news/293778161.md)